Literature DB >> 10088720

CD44 is not an adhesive receptor for osteopontin.

L L Smith1, B W Greenfield, A Aruffo, C M Giachelli.   

Abstract

Osteopontin is a secreted glycoprotein with adhesive and migratory functions. Cellular interactions with osteopontin are mediated through integrin receptors which recognize the RGD domain. Recently, CD44, a non-integrin, multifunctional adhesion molecule was identified as an osteopontin receptor. CD44 is a ubiquitous surface molecule that exists as a number of different isoforms, generated by alternative splicing. To analyze which forms of CD44 mediate binding to osteopontin, we used the standard form of CD44 as CD44-human immunoglobulin fusion proteins and several splice variants in enzyme-linked immunosorbant assays. Multiple preparations of osteopontin were used including native osteopontin derived from smooth muscle cells, human urinary osteopontin, full-length recombinant osteopontin, and two recombinant osteopontin fragments expected to be formed following thrombin cleavage. Our data show that although the CD44-hlg fusion proteins could interact with hyaluronic acid as expected, there was no interaction between CD44H, CD44E, CD44v3,v8-v10, or CD44v3 with osteopontin. These studies suggest that CD44-osteopontin interactions may not be common in vivo and may be limited to a specific CD44 isoform(s), and/or a particular modified form of osteopontin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10088720     DOI: 10.1002/(sici)1097-4644(19990401)73:1<20::aid-jcb3>3.0.co;2-3

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

1.  Thrombin cleavage of osteopontin disrupts a pro-chemotactic sequence for dendritic cells, which is compensated by the release of its pro-chemotactic C-terminal fragment.

Authors:  Zhifei Shao; John Morser; Lawrence L K Leung
Journal:  J Biol Chem       Date:  2014-08-11       Impact factor: 5.157

2.  Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation.

Authors:  Subarna A Khan; Amy C Cook; Maya Kappil; Ursula Günthert; Ann F Chambers; Alan B Tuck; David T Denhardt
Journal:  Clin Exp Metastasis       Date:  2006-05-12       Impact factor: 5.150

Review 3.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

4.  Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes.

Authors:  J M Weiss; A C Renkl; C S Maier; M Kimmig; L Liaw; T Ahrens; S Kon; M Maeda; H Hotta; T Uede; J C Simon
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

5.  Tertiary structure prediction and identification of druggable pocket in the cancer biomarker - Osteopontin-c.

Authors:  Subramaniam Sivakumar; Sivasitambaram Niranjali Devaraj
Journal:  J Diabetes Metab Disord       Date:  2014-01-08

6.  The role of osteopontin in inflammatory processes.

Authors:  Susan Amanda Lund; Cecilia M Giachelli; Marta Scatena
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

7.  Inhibition of Cellular Adhesion by Immunological Targeting of Osteopontin Neoepitopes Generated through Matrix Metalloproteinase and Thrombin Cleavage.

Authors:  Alexander Jürets; Marie Le Bras; Günther Staffler; Gesine Stein; Lukas Leitner; Angelika Neuhofer; Matteo Tardelli; Edvin Turkof; Maximilian Zeyda; Thomas M Stulnig
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

Review 8.  Osteopontin b and c Splice isoforms in Leukemias and Solidzzm321990Tumors: Angiogenesis Alongside Chemoresistance

Authors:  Akram Mirzaei; Saeed Mohammadi; Seyed H Ghaffari; Marjan Yaghmaie; Mohammad Vaezi; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.